Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences

International Journal of COPD

Volumn 9, Issue , 2014, Pages 107-114

  Ohno, Takeshi ^a   Wada, Shota ^a   Hanada, Souichirou ^a   Sawaguchi, Hirochiyo ^a   Muraki, Masato ^a   Tohda, Yuji ^b  

^a KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

COPD; Device; Indacaterol; Quality of life; Respiratory function

Indexed keywords

INDACATEROL; SALMETEROL; TIOTROPIUM BROMIDE;

ADD ON THERAPY; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COPD ASSESSMENT TEST; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOARSENESS; HUMAN; INHALER; INSPIRATORY CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; MOUTH DISCOMFORT; OPEN STUDY; OUTPATIENT; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SUBSTITUTION THERAPY; XEROSTOMIA;

COPD; DEVICE; INDACATEROL; QUALITY OF LIFE; RESPIRATORY FUNCTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; EQUIPMENT DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; LUNG; MALE; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PATIENT PREFERENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLONES; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84892693519     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S56777     Document Type: Article

References (27)

1. Lopez AD, Shibuya K, Rao C, etal. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27: 397-412.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
3. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011;378:991-996.
4. Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481-1490.
5. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B; INSURE Study Investigators. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis. 2010;5:311-318.
6. Dahl R, Chung KF, Buhl R, etal. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.
7. Bleecker ER, Siler T, Owen R, Kramer B. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis. 2011;6: 431-438.
8. Kornmann O, Dahl R, Centanni S, etal. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273-279.
9. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984;311:421-425.
10. Schocken DD, Roth GS. Reduced beta-adrenergic receptor concentrations in ageing man. Nature. 1977;267:856-858.
11. Vogelmeier C, Hederer B, Glaab T, etal. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364: 1093-1103.
12. Vogelmeier C, Ramos-Barbon D, Jack D, etal. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11:135.
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive lung disease [updated 2013]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed December 9, 2013.
14. Vestbo J, Anderson JA, Calverley PM, etal. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64: 939-943.
15. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013;13:26.
16. Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O. Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:1-5.
17. Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adv Exp Med Biol. 2013;756:23-28.
18. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105: 719-726.
19. Feldman GJ. Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol. Int J Chron Obstruct Pulmon Dis. 2013;8:89-96.
20. Segreti A, Fiori E, Calzetta L, etal. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013;26(6): 630-634.
21. Donohue JF, Fogarty C, Lötvall J, etal. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
22. Mahler DA, Buhl R, Lawrence D, McBryan D. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther. 2013;26:348-355.
23. Buhl R, Dunn LJ, Disdier C, etal. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38: 797-803.
24. Mahler DA, D'Urzo A, Bateman ED, etal. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67:781-788.
25. Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung. 2013;191:135-146.
26. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:401-406.
27. Restrepo RD, Alvarez MT, Wittnebel LD, etal. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:371-384.